.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
Covington
Julphar
Accenture
Novartis
Boehringer Ingelheim
QuintilesIMS
Citi
Healthtrust
Cantor Fitzgerald

Generated: June 28, 2017

DrugPatentWatch Database Preview

Claims for Patent: 9,198,858

« Back to Dashboard

Claims for Patent: 9,198,858

Title:Methods of treating bacterial vaginosis with aqueous-based metronidazole gel formulations
Abstract: The present disclosure provides mucoadhesive aqueous-based gel formulations of metronidazole useful for a variety of purposes, including intravaginal application as a therapeutic approach towards the treatment of individuals suffering from and/or diagnosed with bacterial vaginosis.
Inventor(s): Nordsiek; Michael T. (Wayne, PA), Balaji; Kodumudi S. (Landsdale, PA)
Assignee: Watson Pharmaceuticals, Inc. (Salt Lake City, UT)
Application Number:13/593,386
Patent Claims: 1. A method of treating bacterial vaginosis ("BV") comprising a step of: administering to a subject suffering from and/or diagnosed with BV a treatment that consists of a single intravaginal administration of an aqueous-based gel composition containing active agent that consists of about 65 mg metronidazole ("MTZ"), wherein the concentration of MTZ is about 1.3% by weight; and the aqueous-based gel is free of dextrins, cyclodextrins, niacin, niacinamide, and surfactants.

2. The method of claim 1, wherein the step of administering comprises administering a single unit dose of the aqueous-based gel composition, which unit dose contains about 65 mg of MTZ.

3. The method of claim 2, wherein the aqueous-based gel composition comprises one or more gelling polymers, about 1.3% by weight MTZ, a solvent system for MTZ, and water.

4. The method of claim 3, wherein the aqueous-based MTZ gel composition comprises about 1.3 wt % MTZ, about 1 wt % to about 3 wt % of one or more gelling polymers, about 30 wt % to about 60 wt % of a solvent system for the MTZ, and about 30 wt % to about 60 wt % water.

5. The method of claim 3, wherein the solvent system comprises one or more lower aromatic alcohols, one or more lower aliphatic diols and/or one or more polyoxyalkylenes having a molecular weight ranging from about 200 to about 400.

6. The method of claim 5, wherein the one or more lower aromatic alcohols are selected from the group consisting of benzyl alcohol, phenoxyethanol, and mixtures thereof.

7. The method of claim 5, wherein the one or more lower aliphatic diols are selected from the group consisting of ethane-1,2-diol (ethylene glycol), propane-1,2-diol(propylene glycol), and mixtures thereof.

8. The method of claim 5, wherein the one or more lower polyoxyalkylenes are selected from the group consisting of polyoxyethylene (polyethylene glycol), polyoxypropylene (polypropylene glycol), and mixtures thereof.

9. The method of claim 5, wherein the solvent system consists of benzyl alcohol, propane-1,2-diol and PEG 400.

10. The method of claim 3, wherein the aqueous-based MTZ gel composition further comprises one or more preservatives, where the one or more preservatives are optionally esters of 4-hydroxy benzoic acid.

11. The method of claim 3, wherein the aqueous-based MTZ gel composition has a pH in the range about pH 3.0 to about pH 5.0.

12. The method of claim 3, wherein the aqueous-based MTZ gel composition has a pH of about pH 4.0.

13. The method of claim 3, wherein the one or more gelling polymers are selected from the group consisting of a hydroxyethylcellulose, a carbomer, a polycarbophil, and mixtures thereof.

14. The method of claim 3, wherein the aqueous-based MTZ gel composition comprises about 1.3 wt % MTZ, about 2 wt % polycarbophil AA-1, about 2 wt % benzyl alcohol, about 15 wt % propane-1,2-diol, about 25 wt % PEG 400, about 0.02 wt % methyl 4-hydroxybenzoate, and about 0.08 wt % propyl 4-hydroxybenzoate.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Daiichi Sankyo
Moodys
Farmers Insurance
Cipla
Novartis
Merck
Deloitte
Chubb
Mallinckrodt
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot